2 months ago
ONC
AnalystsFaisal KhurshidFaisal Khurshid's Stock Forecasts
AnalystsFaisal Khurshid
Sectors:
Analyst Ranking
Top 6%
#303 out of 5500 analysts
Average Return
+54.62%
Win Rate
54%20 out of 37
Risk vs Reward
Poor
Good
Faisal Khurshid's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Shattuck Labs IncSTTK | +751.16% | $0.86 | $7.32 | 2025-08-14 - 2026-08-13 | Buy |
Shattuck Labs IncSTTK | +414.53% | $1.17 | $6.02 | 2025-03-17 - 2026-03-16 | Buy |
Spyre Therapeutics IncSYRE | +333.90% | $11.80 | $51.20 | 2025-04-08 - 2026-04-07 | Buy |
Protagonist Therapeutics IncPTGX | +148.88% | $58.86 | $146.49 | 2025-09-12 - 2026-09-01 | Buy |
Trevi Therapeutics IncTRVI | +143.59% | $3.12 | $7.60 | 2024-09-09 - 2025-09-08 | Buy |
Faisal Khurshid Analyst Color
Get additional color on Faisal Khurshid's coverage of popular stocks
2 months ago
ABVX
3 months ago
PTCT
Faisal Khurshid's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Shattuck Labs IncSTTK | 3 | Buy | $16.00 | +132.90% | Initiates Coverage On | a month ago |
Beone Medicines LtdONC | 2 | Strong Buy | $380.00 | +5.95% | Upgrades | 2 months ago |
Abivax SaABVX | 3 | Strong Buy | $158.00 | +39.00% | Upgrades | 2 months ago |
Verastem IncVSTM | 2 | Strong Buy | $8.00 | +5.12% | Maintains | 2 months ago |
Ptc Therapeutics IncPTCT | 2 | Strong Buy | $85.00 | +20.46% | Upgrades | 3 months ago |
Syndax Pharmaceuticals IncSNDX | 1 | Strong Buy | $40.00 | +99.00% | Assumes | 5 months ago |
4d Molecular Therapeutics IncFDMT | 1 | Strong Buy | $21.00 | +46.34% | Assumes | 5 months ago |
Protagonist Therapeutics IncPTGX | 2 | Buy | $110.00 | -24.91% | Maintains | 5 months ago |
Kymera Therapeutics IncKYMR | 4 | Strong Buy | $110.00 | -7.60% | Assumes | 6 months ago |
Insmed IncINSM | 1 | Strong Buy | $228.00 | +87.64% | Assumes | 6 months ago |
Cogent Biosciences IncCOGT | 1 | Strong Buy | $55.00 | +58.59% | Assumes | 6 months ago |
Design Therapeutics IncDSGN | 1 | Strong Buy | $15.00 | -0.92% | Initiates Coverage On | 6 months ago |
Alnylam Pharmaceuticals IncALNY | 1 | Hold | $330.00 | +34.09% | Downgrades | 6 months ago |
Incyte CorpINCY | 1 | Hold | $94.00 | -24.81% | Downgrades | 6 months ago |
Trevi Therapeutics IncTRVI | 2 | Buy | $16.00 | -3.44% | Maintains | 9 months ago |
Abcellera Biologics IncABCL | 2 | Hold | $4.00 | -64.54% | Downgrades | 10 months ago |
Lakefront Biotherapeutics NvLKFT | 2 | Buy | $40.00 | +40.11% | Upgrades | 10 months ago |
Contineum Therapeutics IncCTNM | 1 | Buy | $20.00 | +20.85% | Initiates Coverage On | a year ago |
Atyr Pharma IncATYR | 2 | Hold | $1.00 | +110.08% | Downgrades | a year ago |
Rhythm Pharmaceuticals IncRYTM | 2 | Buy | $102.00 | N/A | Maintains | a year ago |
Ironwood Pharmaceuticals IncIRWD | 2 | Hold | $1.00 | N/A | Maintains | a year ago |
Spyre Therapeutics IncSYRE | 1 | Buy | $45.00 | N/A | Initiates Coverage On | a year ago |
Nurix Therapeutics IncNRIX | 1 | Hold | $16.00 | N/A | Initiates Coverage On | a year ago |
Pliant Therapeutics IncPLRX | 2 | Hold | $2.00 | N/A | Downgrades | a year ago |
Ani Pharmaceuticals IncANIP | 1 | Buy | $80.00 | N/A | Initiates Coverage On | 2 years ago |
Zura Bio LtdZURA | 1 | Buy | $15.00 | N/A | Initiates Coverage On | 2 years ago |
Puretech Health PLCPRTCY | 1 | Buy | $45.00 | N/A | Assumes | 2 years ago |
Geron CorpGERN | 1 | Buy | $7.00 | N/A | Initiates Coverage On | 2 years ago |
Mannkind CorpMNKD | 1 | Buy | $8.00 | N/A | Assumes | 2 years ago |
Immunic IncIMUX | 1 | Buy | $50.00 | N/A | Assumes | 2 years ago |
Fusion Pharmaceuticals IncFUSN | 1 | Hold | $21.00 | N/A | Downgrades | 2 years ago |
Rain Oncology IncRAIN2 | 1 | Buy | $11.00 | N/A | Initiates Coverage On | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.